An ongoing controversy over generic equivalents to complex biological drugs is resurfacing in the 2016 session, as patient advocacy groups and drug companies try again to require pharmacists to take extra steps to notify prescribers of a substitution when they dispense something other than a brand-name biological drug.
Jan 29, 2016